

# ZIKA CONGENITAL CASE INVESTIGATION FORM

NCIMS ID:	Date of notification: ___/___/___	Date of interview: ___/___/___
-----------	-----------------------------------	--------------------------------

## DEMOGRAPHIC DETAILS

First Name:		Surname:		DOB:	
Address:		Suburb:		Postcode:	
Phone (home):		Phone (mobile):		Email:	
Indigenous status: <input type="checkbox"/> Aboriginal <input type="checkbox"/> Torres Strait Islander <input type="checkbox"/> Neither		Country of birth: <input type="checkbox"/> Australia <input type="checkbox"/> Other:		Language of Parent: <input type="checkbox"/> English <input type="checkbox"/> Other:	
Interpreter required for case interview: <input type="checkbox"/> Yes <input type="checkbox"/> No    Job Number:					
MOTHER'S DETAILS:		First Name:		Surname:	
				DOB: ___/___/___	
Is Mother a Case on NCIMS?		<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
- If Yes, NCIMS ID:		Classification: <input type="checkbox"/> Confirmed <input type="checkbox"/> Probable <input type="checkbox"/> Suspected			

## LABORATORY EVIDENCE \*

1. Isolation of Zika virus by culture 'Zika virus culture'	<input type="checkbox"/> Yes <input type="checkbox"/> No	Specimen type: <input type="checkbox"/> Serum <input type="checkbox"/> Other:	Collection date: ___/___/___
2. Detection of Zika virus by nucleic acid testing (PCR) 'Zika virus PCR'	<input type="checkbox"/> Yes <input type="checkbox"/> No	Specimen type: <input type="checkbox"/> Serum <input type="checkbox"/> Other:	Collection date: ___/___/___
3. Detection of Zika antibody in serum ** 'Zika virus IgM/IgG antibody IA'	<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Sample 1:</b> Collection date: ___/___/___ <input type="checkbox"/> IgM detected Titre: _____ <input type="checkbox"/> IgG detected Titre: _____	<b>Sample 2:</b> Collection date: ___/___/___ <input type="checkbox"/> IgM detected Titre: _____ <input type="checkbox"/> IgG detected. Titre: _____
		<b>Assessment:</b> <input type="checkbox"/> No significant changes <input type="checkbox"/> IgG seroconversion <input type="checkbox"/> Significant rise in Ab <input type="checkbox"/> x4 or greater rise in IgG	
4. Detection of Zika IgM antibody in cerebrospinal fluid 'Zika virus IgM antibody IA'	<input type="checkbox"/> Yes <input type="checkbox"/> No	Results: <input type="checkbox"/> Zika IgM detected.	Other results: <input type="checkbox"/> Dengue IgM negative <input type="checkbox"/> MVE IgM negative <input type="checkbox"/> West Nile / Kunjin virus IgM negative <input type="checkbox"/> Japanese encephalitis (JE) virus IgM negative
5. Specimen(s) sent to arbovirus reference lab (ICPMR or QHFSS) for parallel testing or confirmation? <input type="checkbox"/> Yes <input type="checkbox"/> No    Date sent: ___/___/___			

**Note:** \* Confirmation of the result by an arbovirus reference laboratory is recommended

\*\* If ZIKV-specific IgG was initially negative and subsequent testing greater than 4 weeks after exposure fails to demonstrate seroconversion the case should be excluded. Refer to the Confirmed or Probable case definitions (see page 2).

## CLINICAL EVIDENCE

6. Where there clinical signs?	<input type="checkbox"/> Yes <input type="checkbox"/> No				
Microcephaly	<input type="checkbox"/> Yes <input type="checkbox"/> No	- If Yes, diagnosed pre-natally by ultrasound?	<input type="checkbox"/> Yes <input type="checkbox"/> No	- Diagnosed at birth?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Other neurological abnormality	<input type="checkbox"/> Yes <input type="checkbox"/> No	- Details:			
Other abnormality	<input type="checkbox"/> Yes <input type="checkbox"/> No	- Details:			

## PREGNANCY / INFANT BIRTH DETAILS

7. Is the case in a fetus or an infant?		<input type="checkbox"/> Fetus <input type="checkbox"/> Infant
If fetal case:	Gestational age: _____ weeks	
	Expected delivery date: ___/___/___	
If infant case:	Delivery date: ___/___/___	
	Gestational age of baby at delivery: _____ weeks	

**EVENT OUTCOME**

<b>8. Was the baby hospitalized?</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No	Details:
<b>9. Outcome:</b>	<input type="checkbox"/> Alive <input type="checkbox"/> Dead <input type="checkbox"/> Unknown	Date of death: / / (if applicable)
<b>10. Place of disease acquisition (for the Mother)</b>	<input type="checkbox"/> Outside of Australia <input type="checkbox"/> In Australia, outside of NSW* <input type="checkbox"/> In NSW* <input type="checkbox"/> Unknown	
<b>11. Country of disease acquisition (for the Mother)</b>	(Regions can also be selected, e.g. South-East Asia)	

\* **Note:** If a case is believed to have been acquired in NSW or elsewhere in Australia, contact CD OnCall immediately.

**CASE MANAGEMENT**

<b>13. Has the case been referred for specialist Paediatric assessment and management?</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown
- If Yes, Paediatrician details (Name, Address, Phone):	
- If No or unknown, action taken:	

**BACKGROUND INFORMATION ON CONGENITAL ZIKA**

- There is strong scientific consensus that pregnant women who become infected with ZIKV can transmit the infection to their unborn babies, with potentially serious consequences.
- Reports from many countries where ZIKV outbreaks have occurred indicate an association between maternal infection and risk of severe congenital abnormalities, including microcephaly.
- While the risk appears greatest with infection in the first trimester, the risk of congenital abnormalities and complications appears to relate to all trimesters of pregnancy.
- Maternal ZIKV infection is not believed to pose a risk of birth defects for future pregnancies.

**ZIKA CONGENITAL CASE DEFINITIONS \***

<b>A CONFIRMED Congenital Zika case requires:</b>	<b>A PROBABLE Congenital Zika case requires:</b>
<ul style="list-style-type: none"> <li>• Laboratory definitive evidence only. (cases are further classified as Fetal or Infant)</li> </ul>	<ul style="list-style-type: none"> <li>• Clinical evidence <b>AND</b> epidemiological evidence. (cases are further classified as Fetal or Infant)</li> </ul>
<p><b>Laboratory definitive evidence</b></p> <p>Fetal case (at 20 weeks gestation or more):</p> <ul style="list-style-type: none"> <li>• Isolation or detection of ZIKV from appropriate clinical samples (i.e. fetal blood, amniotic fluid, chorionic villus sample or post-mortem cerebrospinal fluid or tissue) by viral culture or nucleic acid testing.</li> </ul> <p>Infant (within 28 days following birth):</p> <ul style="list-style-type: none"> <li>• Isolation or detection of ZIKV from appropriate clinical samples by viral culture or nucleic acid testing, with no history of travel since birth to, or residence in, a ZIKV receptive country or area in Australia</li> </ul>	<p><b>Clinical evidence</b></p> <ul style="list-style-type: none"> <li>• Microcephaly or other CNS abnormalities in the infant or fetus (in the absence of any other known cause).</li> </ul> <p><b>Epidemiological evidence</b></p> <ul style="list-style-type: none"> <li>• Confirmed or probable ZIKV infection in the mother during pregnancy.*</li> </ul>
<b>Note:</b> * See the Zika control guidelines for other Zika case definitions.	

<b>ADDITIONAL NOTES:</b>
--------------------------